This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Stroke	Adenosine A ₃ receptor (ADORA ₃)	A study in cell and tissue cultures identified a triazolopyrazinone-based ADORA₃ antagonist that may help treat stroke. In rat hippocampal tissue slices, 10nM of the triazolopyrazinone derivative prevented or delayed the neuronal depolarization that can lead to the irreversible loss of neurotransmission. Also in the rat hippocampal slices, the derivative induced significant recovery of neurotransmission compared with that seen using no treatment ($p<0.001$). Next steps could include evaluating the ADORA₃ antagonist in animal stroke models. DT0738, a small molecule antagonist of ADORA₃ from Domain Therapeutics S.A., is in preclinical testing for glaucoma. SciBX 2(14); doi:10.1038/scibx.2009.594 Published online April 9, 2009	Patent and licensing status unavailable	Colotta, V. <i>et al. J. Med. Chem.</i>; published online March 20, 2009; doi:10.1021/jm8014876 Contact: Vittoria Colotta, University of Firenze, Firenze, Italy e-mail: vittoria.colotta@unifi.it